Qiagen

QGEN

Market cap $10.3B

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 3.

QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.

Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.64 per share a year ago.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,.

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN's entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo.

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there's renewed takeover speculation after reports that show they're weighing strategic options. QGEN's potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Ket.